Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, adding:
”Choosing the right anticoagulant for acute venous thromboembolism (VTE) often comes down to balancing efficacy with bleeding risk.
A recent international randomized trial compared apixaban and rivaroxaban, two of the most commonly used direct oral anticoagulants for treating acute pulmonary embolism and proximal deep-vein thrombosis.
Study design
- 2,760 patients with acute symptomatic VTE
- Randomized 1:1 to apixaban or rivaroxaban
- 3-month treatment period
- Primary endpoint: clinically relevant bleeding (major plus clinically relevant non-major bleeding)
Dosing
- Apixaban: 10 mg BID for 7 days – 5 mg BID
- Rivaroxaban: 15 mg BID for 21 days – 20 mg daily
Key results
Clinically relevant bleeding:
- Apixaban: 3.3%
- Rivaroxaban: 7.1%
- Relative risk: 0.46 (95% CI 0.33–0.65, P < 0.001)
This represents ~54% lower risk of clinically relevant bleeding with apixaban over the 3-month treatment period.
Mortality remained very low in both groups
- Apixaban: 0.1%
- Rivaroxaban: 0.3%
Takeaway
Among patients with acute VTE, apixaban demonstrated a significantly lower bleeding risk compared with rivaroxaban, while maintaining similar overall safety outcomes.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger, for the COBRRA Trial Investigators
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 22, 2026, 07:56Shruti Kharat: Closing the Gap in Early Detection of Factor VIII Inhibitors
-
Apr 22, 2026, 07:46Gregory Piazza: Ushering in a New Era in PE Therapy and Improved Clinical Outcomes for Our Patients
-
Apr 22, 2026, 07:40Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
-
Apr 22, 2026, 07:36Selma Turkovic: Blood Transfusion Education and Discussion Group Webinar 61
-
Apr 22, 2026, 07:34Aikati Anastasiou: Advancing Stroke Imaging Insights from the DISTAL Trial
-
Apr 22, 2026, 07:26Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?
-
Apr 22, 2026, 07:19Sarah Richardson: Bringing Insights from HFA Symposium Back to Real Life
-
Apr 22, 2026, 07:17Karuna Kumar: Interesting Trial from Gambia on Treating Iron Deficiency in Children
-
Apr 22, 2026, 07:12Mary Catherine Moffett: Celebrating 32 Years of Patient-Centered Advocacy with the Hemophilia Federation of America